A Dose Escalation, Safety, Pharmacokinetic, Pharmacodynamic and Preliminary Efficacy Study of SAR650984 (Isatuximab) Administered Intravenously in Combination With Bortezomib - Based Regimens in Adult Patients With Newly Diagnosed Multiple Myeloma Non Eligible for Transplantation

Trial Profile

A Dose Escalation, Safety, Pharmacokinetic, Pharmacodynamic and Preliminary Efficacy Study of SAR650984 (Isatuximab) Administered Intravenously in Combination With Bortezomib - Based Regimens in Adult Patients With Newly Diagnosed Multiple Myeloma Non Eligible for Transplantation

Recruiting
Phase of Trial: Phase I

Latest Information Update: 10 Dec 2017

At a glance

  • Drugs Isatuximab (Primary) ; Bortezomib; Cyclophosphamide; Dexamethasone; Dexamethasone
  • Indications Multiple myeloma
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms CyBorDSAR
  • Sponsors Sanofi
  • Most Recent Events

    • 07 Dec 2017 According to a Sanofi media release, data from this study will be presented at upcoming American Society of Hematology meeting.
    • 27 Sep 2017 Planned End Date changed from 3 Oct 2024 to 18 Nov 2024.
    • 27 Sep 2017 Planned primary completion date changed from 3 Oct 2024 to 18 Nov 2024.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top